US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences.
Osteoporosis is a common and serious complication of glucocorticoid therapy. Recent advances in the epidemiology, pathophysiology, and management of glucocorticoid-induced osteoporosis have stimulated the development of guidelines for the prevention and treatment of this condition. In this report, the updated recommendations of the American College of Rheumatology and guidelines recently produced by the Bone and Tooth Society, National Osteoporosis Society, and Royal College of Physicians in the UK are discussed with respect to their similarities and differences.
Compston
Juliet
J
Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Box 157, Cambridge, CB2 2QQ, UK. jec1001@cam.ac.uk
D015502:Absorptiometry, Photon; D050723:Fractures, Bone / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D006113:United Kingdom; D014481:United States
D005938:Glucocorticoids